Next-Generation COVID-19 mAb
COVID-19
Preclinical/DiscoveryActive
Key Facts
About Invivyd
Invivyd's mission is to deliver protection from serious viral infectious diseases by developing rapidly-adaptable monoclonal antibody therapies. The company has achieved key milestones, including positive Phase 3 results for its COVID-19 candidate and an Emergency Use Authorization from the U.S. FDA. Its strategy leverages a proprietary, integrated technology platform to monitor viral evolution and engineer potent, variant-resistant antibodies, positioning it as a critical player in pandemic preparedness and the management of endemic viral diseases.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |